Liang Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Liang Peng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Cao Ma
Department of Pathology, Zhongda Hospital, School of Medicine Southeast University Nanjing China
1 shared publication Haiyu Tang
Department of Cardiovascular, Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital Central China Fuwai Hospital of Zhengzhou University Henan 450003 P. R. China
1 shared publication- Kang Zhao
Department of Cardiovascular, Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital Central China Fuwai Hospital of Zhengzhou University Henan 450003 P. R. China
1 shared publication Lan Guo
School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China
1 shared publicationLinghuan Gao
School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China
1 shared publication- Muwei Li
Department of Hand Surgery, Longgang Orthopedics Hospital of Shenzhen, Shenzhen, PR China
1 shared publication
Latest Publications
- 27 January 2022
- Published by Springer Nature in Cellulose
- Vol. 29 (3) , 1315-1330
Chitosan hydrogel, as a biological macromolecule-based drug delivery system for exosomes and microvesicles in regenerative medicine: a mini review
- 27 January 2022
- Published by Springer Nature in Cellulose
- Vol. 29 (3) , 1315-1330
Chitosan hydrogel, as a biological macromolecule-based drug delivery system for exosomes and microvesicles in regenerative medicine: a mini review
- 21 October 2021
- Published by Wiley in Macromolecular Bioscience
- Vol. 22 (4) , 2100286
Evaluation of an Injectable Hydrogel Based on Hyaluronic Acid–Chitosan/β‐Glycerophosphate‐Loaded Mesenchymal Stem Cells in Enhancing the Therapeutic Efficacy of Myocardial Infarction
Myocardial infarction (MI), which is due to cardiac dysfunction, results in morbidity and mortality. Moreover, the cellular activity of transplanted mesenchymal stem cells (MSCs) generally limits their therapeutic efficacy in the treatment of MI. Here, inject able hyaluronic acid‐chitosan/β‐glycerophosphate (HA–CS/β‐GP) hydrogel‐loaded MSCs are prepared, after which their effects on the treatment of MI are investigated. The synthesized HA–CS/β‐GP hydrogels exhibit swelling ratio, an in vitro degradation value, and a gelatin time of 82.19 ± 4.1, 88.18% ± 2.4%, and 9 s, respectively. Further, rheological studies revealed that the elastic modulus of the HA–CS/β‐GP hydrogels is ≥230 Pa, exhibiting large elastic to viscous modulus ratio, which indicates their mechanical strength. Furthermore, the in vitro 3T3 cell and MSC culture studies confirm the good biocompatibility of the HA–CS and HA–CS/β‐GP hydrogels. The implantation of the synthesized hydrogels in the mouse MI model considerably improves the therapeutic effect of the MSCs (enhanced cardiac function, reduced cardiomyocyte apoptosis, and increased vascularization) for the first time. The innovative synergistic strategy of combining injectable HA–CS and HA–CS/β‐GP hydro gels with MSCs may be suitable for the effective treatment of cardiac morbidity due to MIs.
- 21 October 2021
- Published by Wiley in Macromolecular Bioscience
- Vol. 22 (4) , 2100286
Evaluation of an Injectable Hydrogel Based on Hyaluronic Acid–Chitosan/β‐Glycerophosphate‐Loaded Mesenchymal Stem Cells in Enhancing the Therapeutic Efficacy of Myocardial Infarction
Myocardial infarction (MI), which is due to cardiac dysfunction, results in morbidity and mortality. Moreover, the cellular activity of transplanted mesenchymal stem cells (MSCs) generally limits their therapeutic efficacy in the treatment of MI. Here, inject able hyaluronic acid‐chitosan/β‐glycerophosphate (HA–CS/β‐GP) hydrogel‐loaded MSCs are prepared, after which their effects on the treatment of MI are investigated. The synthesized HA–CS/β‐GP hydrogels exhibit swelling ratio, an in vitro degradation value, and a gelatin time of 82.19 ± 4.1, 88.18% ± 2.4%, and 9 s, respectively. Further, rheological studies revealed that the elastic modulus of the HA–CS/β‐GP hydrogels is ≥230 Pa, exhibiting large elastic to viscous modulus ratio, which indicates their mechanical strength. Furthermore, the in vitro 3T3 cell and MSC culture studies confirm the good biocompatibility of the HA–CS and HA–CS/β‐GP hydrogels. The implantation of the synthesized hydrogels in the mouse MI model considerably improves the therapeutic effect of the MSCs (enhanced cardiac function, reduced cardiomyocyte apoptosis, and increased vascularization) for the first time. The innovative synergistic strategy of combining injectable HA–CS and HA–CS/β‐GP hydro gels with MSCs may be suitable for the effective treatment of cardiac morbidity due to MIs.